Roche’s phase 1 mystery
Could RO7851624, newly into clinical trials, be RG6735?
FDA red and green lights: April 2026
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The month ahead: May’s upcoming events
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
New clinical projects from Kumquat and Context
The two companies have been involved in recent licensing deals.
June’s first Dispatch reaches patients
Dispatch Bio’s virus therapy DV-10 enters phase 1.
Pluvicto gets a no in Europe
Unlike the US FDA, the CHMP doesn't recommend approval for pre-chemo prostate cancer.
